FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226175083> ?p ?o ?g. }

• W4226175083 endingPage "1311" @default.
• W4226175083 startingPage "1301" @default.
• W4226175083 abstract "PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non–small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.53 to 0.87; P = .00251) and progression-free survival (PFS [blinded independent central review; RECIST v1.1]; stratified HR, 0.52; 95% CI, 0.42 to 0.65; P < .0001), with manageable safety. We report updated, exploratory analyses of survival, approximately 5 years after the last patient was randomly assigned. METHODS Patients with WHO performance status 0 or 1 (any tumor programmed cell death-ligand 1 status) were randomly assigned (2:1) to durvalumab (10 mg/kg intravenously; administered once every 2 weeks for 12 months) or placebo, stratified by age, sex, and smoking history. Time-to-event end point analyses were performed using stratified log-rank tests. Medians and landmark survival rates were estimated using the Kaplan-Meier method. RESULTS Seven hundred and nine of 713 randomly assigned patients received durvalumab (473 of 476) or placebo (236 of 237). As of January 11, 2021 (median follow-up, 34.2 months [all patients]; 61.6 months [censored patients]), updated OS (stratified HR, 0.72; 95% CI, 0.59 to 0.89; median, 47.5 v 29.1 months) and PFS (stratified HR, 0.55; 95% CI, 0.45 to 0.68; median, 16.9 v 5.6 months) remained consistent with the primary analyses. Estimated 5-year rates (95% CI) for durvalumab and placebo were 42.9% (38.2 to 47.4) versus 33.4% (27.3 to 39.6) for OS and 33.1% (28.0 to 38.2) versus 19.0% (13.6 to 25.2) for PFS. CONCLUSION These updated analyses demonstrate robust and sustained OS and durable PFS benefit with durvalumab after chemoradiotherapy. An estimated 42.9% of patients randomly assigned to durvalumab remain alive at 5 years and 33.1% of patients randomly assigned to durvalumab remain alive and free of disease progression, establishing a new benchmark for standard of care in this setting." @default.
• W4226175083 created "2022-05-05" @default.
• W4226175083 creator A5004864286 @default.
• W4226175083 creator A5005962138 @default.
• W4226175083 creator A5007121755 @default.
• W4226175083 creator A5007868555 @default.
• W4226175083 creator A5017446958 @default.
• W4226175083 creator A5018054038 @default.
• W4226175083 creator A5021704329 @default.
• W4226175083 creator A5023874099 @default.
• W4226175083 creator A5028596081 @default.
• W4226175083 creator A5035680745 @default.
• W4226175083 creator A5038306289 @default.
• W4226175083 creator A5041718881 @default.
• W4226175083 creator A5044692746 @default.
• W4226175083 creator A5045629779 @default.
• W4226175083 creator A5046273815 @default.
• W4226175083 creator A5052765751 @default.
• W4226175083 creator A5052930984 @default.
• W4226175083 creator A5060572768 @default.
• W4226175083 creator A5063817865 @default.
• W4226175083 creator A5064697305 @default.
• W4226175083 creator A5072962250 @default.
• W4226175083 creator A5075417603 @default.
• W4226175083 creator A5077453712 @default.
• W4226175083 creator A5091073688 @default.
• W4226175083 creator A5091892222 @default.
• W4226175083 date "2022-04-20" @default.
• W4226175083 modified "2023-10-18" @default.
• W4226175083 title "Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer" @default.
• W4226175083 cites W1968899146 @default.
• W4226175083 cites W2104701073 @default.
• W4226175083 cites W2110469369 @default.
• W4226175083 cites W2118397697 @default.
• W4226175083 cites W2140469315 @default.
• W4226175083 cites W2149089484 @default.
• W4226175083 cites W2263280562 @default.
• W4226175083 cites W2586810147 @default.
• W4226175083 cites W2753065806 @default.
• W4226175083 cites W2893824814 @default.
• W4226175083 cites W2909427482 @default.
• W4226175083 cites W2952953974 @default.
• W4226175083 cites W2978349873 @default.
• W4226175083 cites W2980537150 @default.
• W4226175083 cites W2995072671 @default.
• W4226175083 cites W3010768695 @default.
• W4226175083 cites W3015017936 @default.
• W4226175083 cites W3028746215 @default.
• W4226175083 cites W3094020015 @default.
• W4226175083 cites W3107857442 @default.
• W4226175083 cites W3108819942 @default.
• W4226175083 cites W3129359084 @default.
• W4226175083 cites W3134670533 @default.
• W4226175083 cites W3152496927 @default.
• W4226175083 doi "https://doi.org/10.1200/jco.21.01308" @default.
• W4226175083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35108059" @default.
• W4226175083 hasPublicationYear "2022" @default.
• W4226175083 type Work @default.
• W4226175083 citedByCount "335" @default.
• W4226175083 countsByYear W42261750832022 @default.
• W4226175083 countsByYear W42261750832023 @default.
• W4226175083 crossrefType "journal-article" @default.
• W4226175083 hasAuthorship W4226175083A5004864286 @default.
• W4226175083 hasAuthorship W4226175083A5005962138 @default.
• W4226175083 hasAuthorship W4226175083A5007121755 @default.
• W4226175083 hasAuthorship W4226175083A5007868555 @default.
• W4226175083 hasAuthorship W4226175083A5017446958 @default.
• W4226175083 hasAuthorship W4226175083A5018054038 @default.
• W4226175083 hasAuthorship W4226175083A5021704329 @default.
• W4226175083 hasAuthorship W4226175083A5023874099 @default.
• W4226175083 hasAuthorship W4226175083A5028596081 @default.
• W4226175083 hasAuthorship W4226175083A5035680745 @default.
• W4226175083 hasAuthorship W4226175083A5038306289 @default.
• W4226175083 hasAuthorship W4226175083A5041718881 @default.
• W4226175083 hasAuthorship W4226175083A5044692746 @default.
• W4226175083 hasAuthorship W4226175083A5045629779 @default.
• W4226175083 hasAuthorship W4226175083A5046273815 @default.
• W4226175083 hasAuthorship W4226175083A5052765751 @default.
• W4226175083 hasAuthorship W4226175083A5052930984 @default.
• W4226175083 hasAuthorship W4226175083A5060572768 @default.
• W4226175083 hasAuthorship W4226175083A5063817865 @default.
• W4226175083 hasAuthorship W4226175083A5064697305 @default.
• W4226175083 hasAuthorship W4226175083A5072962250 @default.
• W4226175083 hasAuthorship W4226175083A5075417603 @default.
• W4226175083 hasAuthorship W4226175083A5077453712 @default.
• W4226175083 hasAuthorship W4226175083A5091073688 @default.
• W4226175083 hasAuthorship W4226175083A5091892222 @default.
• W4226175083 hasBestOaLocation W42261750831 @default.
• W4226175083 hasConcept C121608353 @default.
• W4226175083 hasConcept C126322002 @default.
• W4226175083 hasConcept C141071460 @default.
• W4226175083 hasConcept C142724271 @default.
• W4226175083 hasConcept C168563851 @default.
• W4226175083 hasConcept C203092338 @default.
• W4226175083 hasConcept C204787440 @default.
• W4226175083 hasConcept C207103383 @default.
• W4226175083 hasConcept C27081682 @default.
• W4226175083 hasConcept C2776256026 @default.

• next